Overview

Sintilimab in FH-deficient Renal Cell Carcinoma

Status:
Not yet recruiting
Trial end date:
2023-04-01
Target enrollment:
Participant gender:
Summary
This is a single-arm phase II clinical trial to evaluate the initial efficacy and safety of Sintilimab, a PD-1 Inhibitor, as Second-line Treatment in FH-deficient Renal Cell Carcinoma.
Phase:
Phase 2
Details
Lead Sponsor:
West China Hospital